

2026 Affiliate Conference: Pharmacist Track

This program is offered by the Department of Pharmacy and Pharmaceutical Sciences

When: March 13th, 2026 (8:00 am – 4:00 pm)

Where: St. Jude Children's Research Hospital (Memphis, TN) – Marlo Thomas Center (MTC)
and via Webex (link provided by CME staff)

Activity Type: Knowledge

Target Audience: Pharmacists

Credit: 45 minutes (0.75 CEU) is available per session

Conference Objectives:

At the end of this session, attendees will be able to:

1. Recognize the benefits of collaboration in the care of pediatric hematology and oncology patients
2. Describe advances in supportive care therapy for patients with hematologic and oncologic conditions
3. Describe advanced in laboratory testing that may impact the treatment of hematologic and oncologic conditions

Disclosures:

There are no relevant financial relationships in the last 24 months to disclose for any person with control over the content of these presentations.



Sommer Brannan, MSN, APRN, FNP-C ¹



Linzie Roberts, PharmD ²



Amanda Carlson, PharmD, BCPS ³

8:00-8:45 am

Preservation of Reproductive Health in
Pediatric Hematology/Oncology
Populations

Activity Type: Knowledge
UAN: 0181-0000-26-006-L01-P

Learning Objectives:

1. TBD
2. TBD
3. TBD

8:50-9:35 am

Pediatric Immune Thrombocytopenia
(ITP): Guideline Review and Overcoming
Medication Access Barriers in Pediatric
Patients

Activity Type: Knowledge
UAN: 0181-0000-26-013-L01-P

Learning Objectives:

1. Describe the diagnostic criteria and classification of pediatric immune thrombocytopenia (ITP) including features that warrant additional evaluation.
2. Recognize ASH 2019 guideline recommendation's role in evidence-based treatment plans for pediatric ITP, including appropriate use and sequencing of TPO-receptor agonists
3. Summarize real-world medication access barriers to ensure timely initiation and continuation of TPO-receptor agonist therapy in pediatric ITP

10:30-11:15 am

Vaccinating the High-Risk Pediatric
Patient: Sickle Cell Disease and Post-
Cellular Therapy

Activity Type: Knowledge
UAN: 0181-0000-26-007-L01-P

Learning Objectives:

1. Identify the most common causes of pneumonia based on age and associated signs and symptoms.
2. Discuss the impact of a pneumonia (PNA) pathogen multiplex PCR (mPCR) panel on time to first and complete antimicrobial therapy optimization in hospitalized pediatric patients with pneumonia compared with bacterial and/or viral respiratory cultures alone.

¹ Nurse Practitioner: APP for Preservation of Reproductive Health; St. Jude Children's Research Hospital
^{2/3} Pharmacist, Affiliate Program – 2 Tulsa/ 3 Springfield; St. Jude Children's Research Hospital

		
<p>Caroline Flint, PharmD, BCPPS ⁴</p>	<p>Shervin Izadian, PharmD, BCIDP ⁵</p>	<p>Katherine Robinson, PharmD, MS, BCPS⁴ Patricia 'PJ' Barker, PharmD, BCPPS ⁴</p>
<p>11:15am-12:00 pm</p> <p>Vaccinating the High-Risk Pediatric Patient: Sickle Cell Disease and Post-Cellular Therapy</p> <p>Activity Type: Knowledge UAN: 0181-0000-26-008-L01-P</p> <p>Learning Objectives:</p> <ol style="list-style-type: none"> 1. Describe how vaccination recommendations for children with sickle cell disease differs from the routine pediatric population. 2. Explain the timing and revaccination strategies for pediatric patients after hematopoietic cell transplant (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy. 	<p>2:15-3:00 pm</p> <p>Evidence-Based Strategies for Prevention and Treatment of Chemotherapy Induced Nausea and Vomiting</p> <p>Activity Type: Knowledge UAN: 0181-0000-26-009-L01-P</p> <p>Learning Objectives:</p> <ol style="list-style-type: none"> 1. Describe the pathophysiology of chemotherapy-induced nausea and vomiting 2. Classify chemotherapy regimens into emetogenic risk categories using current pediatric guidelines 3. Select optimal antiemetic regimens aligned with current pediatric guidelines for each emetogenic risk category 	<p>3:15-4:00 pm</p> <p>Pharmacogenomics Across the Continuum of Care</p> <p>Activity Type: Knowledge UAN: 0181-0000-26-010-L01-P</p> <p>Learning Objectives:</p> <ol style="list-style-type: none"> 1. Recognize the utility of pharmacogenomics for pediatric cancer patients during active treatment and survivorship. 2. Describe how pharmacogenomics influences thiopurine metabolite monitoring and dose adjustments. 3. Identify barriers and facilitators to the use of pharmacogenomic test results across the lifespan.

⁴ Clinical Pharmacy Specialist; St. Jude Children's Research Hospital

⁵ Clinical Staff Pharmacist; St. Jude Children's Research Hospital



The St. Jude Children's Research Hospital Department of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. All activities are offered at no cost to participants and without external financial support unless explicitly stated in program material. Pharmacy continuing education credit will be available to all participants who attend and complete a post-program test & evaluation. Credits will be uploaded and viewable online at nabp.pharmacy within approximately two weeks following the date of the presentation.

For more information, please the St. Jude Pharmacy Education program (pharmedu@stjude.org).

System requirements: [Webex](#) / [Teams](#) / [Google Chrome](#) / [Microsoft Edge](#)